# Final Report: Idea 68

## Final ELO Score: 1193.9

## Final Hypothesis

**Title**: Aerosolised D-Stapled/Macrocyclic Peptides that Irreversibly Quench AgrC Signalling

**Key Idea**: A macrocyclic, partly D-amino stapled peptide with a perfluoroaryl covalent capture group will trap AgrC in an inactive dimer, suppressing MRSA toxins after pulmonary delivery.

**Paragraph**: D-residues improved stability, yet reversible binding still allows wash-out.  Incorporating a perfluoroaryl “SNAr-capture” residue covalently links the inhibitor to a conserved AgrC lysine, enabling once-daily inhalation therapy for MRSA pneumonia.  Pulmonary delivery reduces systemic exposure and resistance pressure.

**Approach**: Structure-guided placement of perfluoroaryl warhead; LC-MS confirmation of adduct; dry-powder formulation (spray-freeze-dry); murine pneumonia efficacy & cytokine profiles.

**Key References**: Novick 2008; Walensky 2004; Schafmeister 2016; NEW—Bruin & Turner, J. Am. Chem. Soc., 2021 (perfluoroaryl capture) [Bruin 2021]; Telko & Hickey, Adv. Drug Deliv. Rev., 2022 (inhaled peptides) [Telko 2022].  
Modifications: Added covalent-capture chemistry and dry-powder aerosol route to bolster potency/duration and feasibility.

────────────────────────────────────────────────────────
IDEA 33  
────────────────────────────────────────────────────────

## Comprehensive Analysis

This document provides a full analysis of the idea, including its evolution, strengths, weaknesses, and potential applications. Below we trace the development of this idea through each phase of the research process.

## Evolution History

The idea underwent several iterations during the research process:

## Detailed Breakdown

### Title

Aerosolised D-Stapled/Macrocyclic Peptides that Irreversibly Quench AgrC Signalling

### Key Idea

A macrocyclic, partly D-amino stapled peptide with a perfluoroaryl covalent capture group will trap AgrC in an inactive dimer, suppressing MRSA toxins after pulmonary delivery.

### Detailed Explanation

D-residues improved stability, yet reversible binding still allows wash-out.  Incorporating a perfluoroaryl “SNAr-capture” residue covalently links the inhibitor to a conserved AgrC lysine, enabling once-daily inhalation therapy for MRSA pneumonia.  Pulmonary delivery reduces systemic exposure and resistance pressure.

### Implementation Approach

Structure-guided placement of perfluoroaryl warhead; LC-MS confirmation of adduct; dry-powder formulation (spray-freeze-dry); murine pneumonia efficacy & cytokine profiles.

### Key References

Novick 2008; Walensky 2004; Schafmeister 2016; NEW—Bruin & Turner, J. Am. Chem. Soc., 2021 (perfluoroaryl capture) [Bruin 2021]; Telko & Hickey, Adv. Drug Deliv. Rev., 2022 (inhaled peptides) [Telko 2022].  
Modifications: Added covalent-capture chemistry and dry-powder aerosol route to bolster potency/duration and feasibility.

────────────────────────────────────────────────────────
IDEA 33  
────────────────────────────────────────────────────────

## Complete Evolution History

This section documents the complete evolution of the idea through each phase of the research process.

### 1. Evolution (Round 4)
**Timestamp:** 2025-05-07 10:43:26



### 2. Reflection (Round 4)
**Timestamp:** 2025-05-07 10:44:53



### 3. Proximity Check (Round 4)
**Timestamp:** 2025-05-07 10:45:31



### 4. Ranking (Round 4)
**Timestamp:** 2025-05-07 10:45:39



### 5. Round Summary (Round 4)
**Timestamp:** 2025-05-07 10:46:18



### 6. Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1193.9



### 7. Final Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1193.9



## Citations

- Bruin 2021
- Telko 2022
